Fri, February 10, 2023
Thu, February 9, 2023
Wed, February 8, 2023

Balaji Prasad Maintained (TEVA) at Buy with Increased Target to $14 on, Feb 9th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-increased-target-to-14-on-feb-9th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Balaji Prasad of Barclays, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Buy with Increased Target from $13 to $14 on, Feb 9th, 2023.

Balaji has made no other calls on TEVA in the last 4 months.



There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Balaji's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Glen Santangelo of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $12 on, Thursday, January 19th, 2023
  • Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $10 on, Monday, November 7th, 2022


These are the ratings of the 2 analyists that currently disagree with Balaji


  • David Amsellem of "Piper Sandler" Maintained at Sell with Decreased Target to $7 on, Wednesday, November 23rd, 2022
  • Chris Schott of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $10 on, Monday, November 14th, 2022

Publication Contributing Sources